Outcomes using direct-acting antiviral hepatitis-C treatment in older versus younger Veterans.

Abstract

BACKGROUND\nHistorically, older adults have been excluded from trials evaluating hepatitis C virus (HCV) treatment, in part, due to the adverse effects associated with previous regimens. Veterans are at high risk of HCV infection. Ledipasvir/sofosbuvir (LED/SOF) is a once daily antiviral regimen with demonstrated efficacy and tolerability among the younger population. We examined the tolerability and effectiveness of LED/SOF in Veterans age ≥65\u2009years versus those <65\u2009years who were treated at the Atlanta VA Health Care System (AVAHCS).\n\n\nMETHODS\nUsing the VA Clinical Case Registry, all persons who filled a LED/SOF prescription at the AVAHCS from January 1, 2015, through March 31, 2016, were identified. The electronic medical records were reviewed to identify basic demographic information: comorbidities; polypharmacy; and outcomes. Sustained virologic response (SVR) was defined as an undetectable HCV RNA, at least 12\u2009weeks after completing treatment. Descriptive statistics were employed using SAS v9.2.\n\n\nRESULTS\nWe identified 345 Veterans who filled LED/SOF during the study period; 94 were excluded due to exposure to ribavirin and IFN containing regimens; 97 (38.6%) were ≥65\u2009years. Veterans were predominantly black (57%) and male (97%). Cancer was more prevalent among older Veterans (p\xa0=\xa00.047) as was polypharmacy (p\xa0=\xa00.001). Treatment completion rates between older and younger Veterans were not significantly different (99 vs. 95%, respectively; p\xa0=\xa00.16), but significantly more older Veterans achieved SVR (98 vs. 91%; p\xa0=\xa00.03).\n\n\nCONCLUSIONS\nLED/SOF was a well-tolerated and effective regimen in an older Veteran population despite their multiple comorbidities and polypharmacy presence.